Caredx, INC 10-Q quarterly reports

CareDx, Inc. announced robust financial results for the second quarter of 2026, with total revenue reaching $131.9 million and net income soaring to $110.6 million.

CareDx, Inc. announced a significant 39% year-over-year increase in total revenue for the first quarter of 2026, reaching $118 million, driven primarily by a 48% surge in testing services revenue.

CareDx, Inc. announced a return to net income in Q3 2025 with significant revenue growth across its testing services, products, and digital solutions, despite ongoing legal challenges and an unaddressed material weakness in internal controls.

CareDx reports a 6% revenue decline to $86.7 million in Q2 2025, driven by prior period adjustments, but sees growth in product and digital solutions, alongside significant legal developments.

CareDx, a precision medicine company focused on transplant solutions, announced an 18% year-over-year increase in revenue for the first quarter of 2025, reaching $84.7 million, while navigating legal challenges and internal control weaknesses.

CareDx, a precision medicine company, announced a 23% year-over-year revenue increase in the third quarter of 2024, driven by growth in testing services, while navigating legal proceedings and a changing regulatory landscape.

CareDx, a precision medicine company, announced a 31% year-over-year revenue increase in the second quarter of 2024, primarily driven by growth in its testing services.

CareDx's first quarter revenue declined to $72.0 million due to changes in Medicare billing, though testing services patient results grew for the third consecutive quarter.